Briefing
Longitudinal ctDNA monitoring for post-surgical molecular residual disease in patients with stage I-IIIb melanoma.
ctDNA positivity at any postoperative timepoint was associated with shorter RFS (HR 15.0, 95% CI 7.3-31.0, P<0.0001), particularly for distant or regional recurrence (HR 27.0). In a multivariate analysis (n=163), ctDNA positivity remained associated with RFS (HR 10.50, 95% CI 3.891-28.32, P<0.001). The abstract states ctDNA positivity influenced treatment-management changes in 28/38 (73.7%) of patients in whom that question was assessed.
- n: 197 patients; 1,718 plasma samples; retrospective real-world series; median 7 tests per patient over a median 24.7 months
- Assay: Signatera (personalized tumor-informed 16-plex mPCR-NGS)